Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19324253rdf:typepubmed:Citationlld:pubmed
pubmed-article:19324253lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:19324253lifeskim:mentionsumls-concept:C0024501lld:lifeskim
pubmed-article:19324253lifeskim:mentionsumls-concept:C0034656lld:lifeskim
pubmed-article:19324253lifeskim:mentionsumls-concept:C0005821lld:lifeskim
pubmed-article:19324253lifeskim:mentionsumls-concept:C0178602lld:lifeskim
pubmed-article:19324253lifeskim:mentionsumls-concept:C1274040lld:lifeskim
pubmed-article:19324253lifeskim:mentionsumls-concept:C0070166lld:lifeskim
pubmed-article:19324253lifeskim:mentionsumls-concept:C0055729lld:lifeskim
pubmed-article:19324253lifeskim:mentionsumls-concept:C1707455lld:lifeskim
pubmed-article:19324253lifeskim:mentionsumls-concept:C0683598lld:lifeskim
pubmed-article:19324253lifeskim:mentionsumls-concept:C2825951lld:lifeskim
pubmed-article:19324253lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:19324253pubmed:issue13lld:pubmed
pubmed-article:19324253pubmed:dateCreated2009-3-27lld:pubmed
pubmed-article:19324253pubmed:abstractTextThe purpose of this study was to determine the impact of adjunctive cilostazol in patients with high post-treatment platelet reactivity (HPPR) undergoing coronary stenting.lld:pubmed
pubmed-article:19324253pubmed:languageenglld:pubmed
pubmed-article:19324253pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19324253pubmed:citationSubsetAIMlld:pubmed
pubmed-article:19324253pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19324253pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19324253pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19324253pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19324253pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19324253pubmed:statusMEDLINElld:pubmed
pubmed-article:19324253pubmed:monthMarlld:pubmed
pubmed-article:19324253pubmed:issn1558-3597lld:pubmed
pubmed-article:19324253pubmed:authorpubmed-author:ParkSeong-Woo...lld:pubmed
pubmed-article:19324253pubmed:authorpubmed-author:JeongYoung-Ho...lld:pubmed
pubmed-article:19324253pubmed:authorpubmed-author:LeeSeung-Whan...lld:pubmed
pubmed-article:19324253pubmed:authorpubmed-author:HwangJin-Yong...lld:pubmed
pubmed-article:19324253pubmed:authorpubmed-author:KimIn-SukISlld:pubmed
pubmed-article:19324253pubmed:authorpubmed-author:ChoiBong-Ryon...lld:pubmed
pubmed-article:19324253pubmed:authorpubmed-author:KwakChoong...lld:pubmed
pubmed-article:19324253pubmed:authorpubmed-author:SeoMyung-KiMKlld:pubmed
pubmed-article:19324253pubmed:issnTypeElectroniclld:pubmed
pubmed-article:19324253pubmed:day31lld:pubmed
pubmed-article:19324253pubmed:volume53lld:pubmed
pubmed-article:19324253pubmed:ownerNLMlld:pubmed
pubmed-article:19324253pubmed:authorsCompleteYlld:pubmed
pubmed-article:19324253pubmed:pagination1101-9lld:pubmed
pubmed-article:19324253pubmed:meshHeadingpubmed-meshheading:19324253...lld:pubmed
pubmed-article:19324253pubmed:meshHeadingpubmed-meshheading:19324253...lld:pubmed
pubmed-article:19324253pubmed:meshHeadingpubmed-meshheading:19324253...lld:pubmed
pubmed-article:19324253pubmed:meshHeadingpubmed-meshheading:19324253...lld:pubmed
pubmed-article:19324253pubmed:meshHeadingpubmed-meshheading:19324253...lld:pubmed
pubmed-article:19324253pubmed:meshHeadingpubmed-meshheading:19324253...lld:pubmed
pubmed-article:19324253pubmed:meshHeadingpubmed-meshheading:19324253...lld:pubmed
pubmed-article:19324253pubmed:meshHeadingpubmed-meshheading:19324253...lld:pubmed
pubmed-article:19324253pubmed:meshHeadingpubmed-meshheading:19324253...lld:pubmed
pubmed-article:19324253pubmed:meshHeadingpubmed-meshheading:19324253...lld:pubmed
pubmed-article:19324253pubmed:meshHeadingpubmed-meshheading:19324253...lld:pubmed
pubmed-article:19324253pubmed:meshHeadingpubmed-meshheading:19324253...lld:pubmed
pubmed-article:19324253pubmed:year2009lld:pubmed
pubmed-article:19324253pubmed:articleTitleRandomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study.lld:pubmed
pubmed-article:19324253pubmed:affiliationDivision of Cardiology, Department of Internal Medicine, Gyeongsang National University Hospital, Jinju, Korea.lld:pubmed
pubmed-article:19324253pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:19324253pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:19324253pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:19324253pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19324253lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19324253lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19324253lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19324253lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19324253lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19324253lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19324253lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19324253lld:pubmed